Categories
Change Password!
Reset Password!
Ozoralizumab rapidly reduces disease activity and improves function in rheumatoid arthritis patients, irrespective of large joint involvement.
A new post hoc analysis of two Japanese randomized clinical trials reports that ozoralizumab provides rapid and sustained clinical benefits in rheumatoid arthritis (RA) patients, regardless of large joint involvement (LJI)—a subgroup often linked with higher disease burden and worse functional outcomes.
Researchers analyzed data from Japanese people with RA who received ozoralizumab 30 mg every 4 weeks for 52 weeks in two phase trials:
Patients were stratified based on the presence of LJI, defined as swelling in the shoulder, elbow, knee, or ankle. Outcomes assessed were disease activity, physical function, inflammatory biomarkers, and radiographic progression of joint damage. Importantly, trial completion rates were comparable between those with and without LJI in both studies, indicating similar treatment tolerability and adherence.
Those with LJI had substantially greater clinical disease activity index (CDAI) scores at baseline compared with those without LJI. The baseline difference disappeared as early as day 3 after initiating ozoralizumab, with comparable CDAI scores noted at most subsequent time points. Improved patient and physician outcomes: Similar rapid improvements were seen in patient-reported outcomes, physician global assessments, and health assessment questionnaire (HAQ) scores, regardless of LJI status.
In those with LJI, interleukin-6 (IL-6) and matrix metalloproteinase-3 (MMP-3) levels exhibited continuous declines throughout the treatment period. Alteration in the modified total sharp score (mTSS) at week 24 was similar between LJI and non-LJI groups in the OHZORA trial, suggesting comparable protection against structural joint damage. Across both methotrexate-treated and non-treated populations, ozoralizumab illustrated robust and consistent potency, independent of LJI. The results support ozoralizumab as a promising treatment option for RA, including those with clinically challenging large joint disease.
BMJ Journals
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials
Kosuke Ebina et al.
Comments (0)